Richard E. Pratley
Novartis Pharmaceuticals Corporation
Clinical Research and Development
Diabetes and Obesity Section
One Health Plaza
USA
Name/email consistency: high
- Progression from IGT to type 2 diabetes mellitus: the central role of impaired early insulin secretion. Pratley, R.E., Weyer, C. Curr. Diab. Rep. (2002)
- Rapid acting insulinotropic agents: restoration of early insulin secretion as a physiologic approach to improve glucose control. Pratley, R.E., Foley, J.E., Dunning, B.E. Curr. Pharm. Des. (2001)